Elucidation of the molecular mechanism(s) for the non-responsiveness of CD38- AMs to tuberculosis infection
- Institution
- TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR, TX
- Principal investigator
- James Evans Samuel
- Funding
- $191K
- Duration
- 2024–2026
Moonbase score
Still being scored
Abstract
The lung-resident alveolar macrophages (AMs) are the initial host cells infected by inhaled Mycobacterium tuberculosis (Mtb). While traditionally perceived as a conducive environment for Mtb replication and spread, our recent studies using fluorescent Mtb fitness reporter strains and single-cell RNA-sequencing (scRNA-seq) have revealed a more intricate reality. We discovered two primary AM populations in the Mtb-infected lung: SiglecF+ CD38+ pro-inflammatory AMs, which house stressed bacteria and express high levels of Nos2, and SiglecF+ CD38- AMs, which lack Nos2 expression and accommodate replicative bacteria. Intriguingly, our preliminary findings indicate that CD38- AMs, which exhibit limited Mtb containment capabilities, are the predominant infected AM population during the early infection stages. Moreover, intranasal BCG vaccination prior to Mtb exposure significantly reduces the number of Mtb-infected host cells and markedly increases the proportion of CD38+ infected AMs. This suggests a critical role for the CD38+ AM phenotype in triggering a protective immune response following vaccination. Although these AM subsets appear transcriptionally indistinguishable in naive mice, they demonstrate distinct chromatin organization, suggesting that epigenetic factors dictate their response to infection. Our hypothesis is that a higher prevalence of CD38+ AMs within the lung airways leads to improved early inhibition of Mtb proliferation and spread, thereby unveiling a viable avenue for immune mediate control of tuberculosis infection. Specific Aim 1: Elucidate the host molecular mechanisms contributing to the limited response of CD38- AMs to Mtb infection. To decipher the host molecular mechanisms underlying the blunted response of CD38- AMs to Mtb infection, we will employ an integrated multi-omics approach to analyze the changes in chromatin organization and transcription factor activity post-Mtb infection. We will then manipulate the AM immune environment through intranasal BCG vaccination to identify those epigenetic changes that are associated with long-term protection against Mtb infection. Specific Aim 2: Implement CRISPR-based genetic perturbation approaches in macrophages to evaluate the role of selected host responses in Mtb infection. Initially, we will use a CRISPR-based genetic perturbation approach to validate the role of candidate host genes, identified in our existing datasets, in generating pro-inflammatory macrophage responses that control Mtb infection. We will then extend this approach to functionally validate additional targets emerging from Specific Aim 1.
LOADING MOONBASE SCORE
Questions for TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · Texas A&M University Health Science Ctr66
Targeting the gut for stroke neuroprotection; IGF-1 modulation of the blood-gut barrier
Shameena Bake · $534K · 2022–2027
- NIH · Texas A&M University Health Science Ctr51
Development of a human salivary gland-on-a-chip composed of both parenchyma and stroma to model dry mouth caused by radiotherapy
Fei Liu · $410K · 2025–2027
- NIH · Texas A&M University Health Science Ctr48
Mutational cooperativity in TET2-associated hematological malignancies.
Yun Huang · $342K · 2021–2026